



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>			
				Application Number		Divisional of 09/718,693	
				Filing Date		August 22, 2003	
				First Named Inventor		John B. Harley	
				Group Art Unit			
				Examiner Name			
Sheet	1	of	15	Attorney Docket Number		OMRF 177 DIV	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	US Patent Document		Name of Patentee or Applicant of Cited Document	Date of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			
AS		4,244,946		Rivier, et al.	01-13-1981	
		4,305,872		Johnston, et al.	12-15-1981	
		4,316,891		Guillemin, et al.	02-23-1982	
		4,675,382		Murphy	06-23-1987	
		4,792,525		Ruoslahti, et al.	12-20-1988	
		5,637,454		Harley	06-10-1997	
		5,906,820		Bacha	05-25-1999	

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)			
AS		PCT	WO 98/30586		Oklahoma Medical Research Foundation	07-16-1998	
AS		PCT	WO 99/02550		Queensland Institute for Medical Research	01-21-1999	

Examine Signature		Date Considered	8/5/05
-------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to application.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SENT TO: Assistant Commissioner for Patent, Washington, DC 20231.

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complet If Known	
		Application Number	Divisional of 09/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
Examiner Name		Attorney Docket Number	OMRF 177 DIV
Sheet	2	of	15

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AS		ADELSTEIN, et al., <i>Nucl. Med. Biol.</i> 14: 165-169 (1987).	
		ALFORD, <i>Antiviral agents and viral diseases of man</i> 2 <sup>nd</sup> ed. Raven Press: New York, pp. 433-86 (1984).	
		ALSBAUGH, et al., <i>Arthr. Rheum.</i> 19: 711-719 (1976).	
		ALSBAUGH, et al., <i>J. Clin. Invest.</i> 67: 1134-1140 (1981).	
		ASHLEY, et al., "Detection of asymptomatic herpes simplex virus infections after vaccination," <i>J. Virol.</i> 61: 253-258 (1987).	
		BABCOCK, et al., <i>J. Exp. Med.</i> 190: 567-576 (1999).	
		BARNES, <i>Pharma Weekly</i> 1: 11 (1995).	
		BELL, et al., <i>J. Rheumatol.</i> 11: 277-281 (1984).	
		BRAY, et al., "Antibodies Against Epstein-Barr Nuclear Antigen (EBNA) in Multiple Sclerosis CSF, and Two Pentapeptide Sequence Identities Between EBNA and Myelin Basic Protein," <i>Arch. Neurol.</i> 42: 1798-1804 (1992).	
		BRAY, et al., <i>Arch. Neurol.</i> 40: 406-408 (1983).	

Examiner's Signature		Date Considered	8/5/05
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB08A (10-95)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	Divisional of 09/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 3 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AP		BROWNING, et al., <i>J. Immunol.</i> 143: 1859-1867 (1989).	
		CALDERWOOD, et al., "Nucleotide sequence of the Shiga-like toxin genes of <i>Escherichia coli</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 84: 4364-4368 (1987).	
		CATALANO, et al., "Antibodies to Epstein-Barr virus-determined antigens in normal subjects and in patients with seropositive rheumatoid arthritis," <i>Proc. Natl. Acad. Sci. USA</i> 76: 5825-5828 (1979).	
		CHEN, et al., <i>J. Biol. Chem.</i> 266: 18237-18243 (1991).	
		COLOMBATTI, et al., <i>J. Biol. Chem.</i> 261: 3030-3035 (1986).	
		DALLDORF, et al., "The Lymphomas of Brazilian Children," <i>J. Am. Med. Assn.</i> 208: 1365-8 (1969).	
		DEACON, et al., "Detection of Epstein-Barr Virus Antigens and DNA in Major and Minor Salivary Glands Using Immunocytochemistry and Polymerase Chain Reaction: Possible Relationship with Sjogren's Syndrome," <i>J. Pathol.</i> 163: 351-360 (1991).	
		DEACON, et al., "Frequency of EBV DNA Detection in Sjogren's Syndrome," <i>Am J. Med.</i> 92: 453-454 (1992).	
		DEBRUS, et al., "Varicella-zoster virus gene 63 encodes an immediate-early protein that is abundantly expressed during latency," <i>J. Virol.</i> 69: 3240-3245 (1995).	
✓		DEDRICK, et al., <i>Cancer Treat. Rep.</i> 62: 1-11 (1978).	

Examiner's Signature		Date Considered	8/5/05
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete if Known			
		Application Number	Divisional of 09/718,693		
		Filing Date	August 22, 2003		
		First Named Inventor	John B. Harley		
		Group Art Unit			
Examiner Name					
Sheet	4	of	15	Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiners' Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AD		DELEERS, et al., <i>FEBS Lett.</i> 160: 82-86 (1983).	
		DIENER, et al., "Specific Immunosuppression by Immunotoxins Containing Daunomycin," <i>Science</i> 231(4734): 148-150 (1986).	
		DIGARD, et al., "Functional analysis of the herpes simplex virus UL42 protein," <i>J. Virol.</i> 67: 1159-1168 (1993).	
		DITTMER, et al., "A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus," <i>J. Virol.</i> 72: 8309-8315 (1998).	
		DONAHUE, et al., <i>Arch. Int. Med.</i> 155: 1605-1609 (1995).	
		ELEK, et al., <i>Lancet</i> 1: 1-5 (1974).	
		ERTL, et al., "Physical and functional interaction of human cytomegalovirus DNA polymerase and its accessory protein (ICP36) expressed in insect cells," <i>J. Virol.</i> 66: 4126-33 (1992).	
		FERREL, et al., <i>J. Clin. Invest.</i> 67: 681-687 (1981).	
		FINERTY, et al., "Immunization of Cotton-top Tamarins and Rabbits with a Candidate Vaccine Against the Epstein-Barr Virus Based on the Major Viral Envelope Glycoprotein gp340 and Alum," <i>Vaccine</i> 12: 1180-1184 (1994).	
✓		FINERTY, et al., "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cotton-top Tamarins Using the Virus Envelope glycoprotein gp340 Produced from a Bovine Papillomavirus Expression Vector," <i>J. Gen. Virol.</i> 73: 449-453 (1992).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Compleat If Kn wn			
				Applicatl n Number		Divisi nal 109/718,693	
				Filling Date		August 22, 2003	
				First Named Inventor		John B. Harley	
				Group Art Unit			
				Examiner Name			
Sheet	5	of	15	Attorney Docket Number		OMRF 177 DIV	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
AD		FOX, "Sjogren's Syndrome," <i>Current Opin. Rheum.</i> 7: 409-416 (1995).	
		FOX, et al., "Detection of Epstein-Barr Virus-Associated Antigens and DNA in Salivary Gland Biopsies from Patients with Sjogren's Syndrome," <i>J. Immunol.</i> 137: 3162-3168 (1986).	
		FOX, et al., "Potential Role of Epstein-Barr Virus in Sjogren's Syndrome and Rheumatoid Arthritis," <i>J. Rheumatol.</i> 19: 18-24 (1992).	
		GLASSY, et al., <i>J. Immunol. Methods</i> 81: 115 (1985).	
		GOODRICH, et al., <i>Ann. Intern. Med.</i> 118:173-178 (1993).	
		GRAY, et al., "Cloning, nucleotide sequence, and expression in <i>Escherichia coli</i> of the exotoxin A structural gene of <i>Pseudomonas aeruginosa</i> ," <i>Proc. Natl. Acad. Sci. USA</i> 81: 2645-2649 (1984).	
		GREENWOOD, et al., <i>Biochem. J.</i> 89: 114-123 (1963).	
		GRIFFITHS, et al., <i>Cancer Res.</i> 51: 4594-4602 (1991).	
		GU, et al., "First EBV Vaccine Trial in Humans Using Recombinant Vaccinia Virus Expressing the Major Membrane Antigen," <i>Dev. Biol. Stand.</i> 84: 171-177 (1995).	
		GUTIERREZ, et al., "Switching Viral Latency to Viral Lysis: A Novel Therapeutic Approach for Epstein-Barr Virus-Associated Neoplasia," <i>Cancer Res.</i> 56: 969-972 (1996).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Completing Information	
		Application Number	Divisional 109/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
Examiner Name			
Sheet 6 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials <sup>1</sup>	Cite No. <sup>2</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>3</sup>
A		HAAHR, et al., "A Putative New Retrovirus Associated with Multiple Sclerosis and the Possible Involvement of Epstein-Barr Virus in This Disease," <i>Ann. N. Y. Acad. Sci.</i> 724: 148-156 (1996).	
		HALPERN, et al., <i>J. Nucl. Med.</i> 29: 1688-1696 (1988).	
		HARLEY & JAMES, "Epstein-Barr virus infection may be an environmental risk factor for systemic lupus erythematosus in children and teenagers," <i>Arthr. Rheum.</i> 42(8): 1782-1783 (1999).	
		HESLOP, et al., "Long-Term Restoration of Immunity Against Epstein-Barr Virus Infection by Adoptive Transfer of Gene-Modified Virus-Specific T Lymphocytes," <i>Nature Med.</i> 2: 551-555 (1996).	
		HISKEY, <i>Peptides</i> 3: 137 (1981).	
		HO, <i>Cytomegalovirus, biology and infection: current topics in infectious disease</i> Plenum Press: New York, pp. 105-118 (1982).	
		HOCH, et al., "Channels formed by botulinum, tetanus, and diphtheria toxins in planar lipid bilayers: relevance to translocation of proteins across membranes," <i>Proc. Natl. Acad. Sci. USA</i> 82: 1692-1696 (1985).	
		HWANG, et al., <i>Cell</i> 48: 129-136 (1987).	
		INOUE, et al., "Analysis of Antibody Titers to Epstein-Barr Virus Nuclear Antigens in Sera of Patients with Sjogren's Syndrome and with Rheumatoid Arthritis," <i>J. Infect. Dis.</i> 164: 22-28 (1991).	
	✓		ISHII, et al., "Cycloheximide-Induced Apoptosis in Burkitt Lymphoma (BJA-B) Cells with and Without Epstein-Barr Virus Infection," <i>Immunol. Cell Biol.</i> 73: 463-468 (1995).

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Compleat If Kn wn	
		Application Number	Divisi nal 109/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 7 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AN		JAMES & HARLEY, "Linear Epitope Mapping of an Sm B/B' Polypeptide," <i>J. Immunol.</i> 148: 2074-2079 (1992).	
		JAMES, et al., "Immunoglobulin Epitope Spreading and Autoimmune Disease After Peptide Immunization: Sm B/B'-derived PPPGMRPP and PPPGIRGP Induce Spliceosome Autoimmunity," <i>J. Exp. Med.</i> 181: 453-461 (1995).	
		JAMES, et al., "An increased prevalence of Epstein-Barr virus infection in young patients suggests a possible etiology for systemic lupus erythematosus," <i>J. Clin. Invest.</i> 100: 3019-26 (1997).	
		JAMES, et al., <i>Arthr. Rheum.</i> 41: S308 (1998).	
		Jl, <i>Meth. Enzymol.</i> 91: 580-609 (1983).	
		KAHAN, et al., <i>Arthr. Rheum.</i> 28: 961-70 (1985).	
		KARAMERIS, et al., "Detection of the Epstein Barr Viral Genome by an <i>in situ</i> Hybridization Method in Salivary Gland Biopsies from Patients with Secondary Sjogren's Syndrome," <i>Clin. Exp. Rheum.</i> 10: 327-332 (1992).	
		KHANNA, et al., "Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: Implications for cytotoxic T-lymphocyte control of EBV-associated malignancies," <i>J. Virology</i> 70(8): 5357-5362 (1996).	
		KIMURA, et al., <i>Clin. Exp. Immunol.</i> 103: 192-298 (1996).	
✓		KITAGAWA, et al., "Detection of Antibodies to the Epstein-Barr Virus Nuclear Antigens in the Sera from Patients with Systemic Lupus Erythematosus," <i>Immunol. Lett.</i> 17:249-252 (1988).	

Examiner's Signature		Date Considered	8/5/05
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Compleat If Kn wn			
		Application Number	Divisi nal 109/718,693		
		Filing Date	August 22, 2003		
		First Named Inventor	John B. Harley		
		Group Art Unit			
		Examiner Name			
Sheet	8	of	15	Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
A		KOHLER & MILSTEIN, <i>Nature</i> 256: 495-497 (1975).	
		KOHLER & MILSTEIN, <i>Eur. J. Immunol.</i> 6: 511-519 (1976).	
		KOIDE, et al., "Spontaneous establishment of an Epstein-Barr virus-infected fibroblast line from the synovial tissue of a rheumatoid arthritis patient," <i>J. Virol.</i> 71: 2478-2481 (1997).	
		KONDO & YAMANISHI, 24 <sup>th</sup> <i>International Herpesvirus Workshop</i> , July 17-23 (Mass. Inst. Tech.) Abst. 1.016 (1999).	
		KONDO, et al., "Human cytomegalovirus latent gene expression in granulocyte-macrophage progenitors in culture and in seropositive individuals," <i>Proc. Natl. Acad. Sci. USA</i> 93: 11137-1142 (1996).	
		KOYAMA, et al., <i>Chem. Abstr.</i> 120: 217-262 (1994).	
		KRAUSE & STRAUSS, <i>Infect. Dis. Clin. N.A.</i> 13: 61-81 (1999).	
		LARSEN, et al., "Epstein-Barr Nuclear Antigen and Viral Capsid Antigen Antibody Titers in Multiple Sclerosis," <i>Neurology</i> 35: 435-438 (1985).	
		LAZAROVITS, et al., "Anti-B Cell Antibodies for the Treatment of Monoclonal Epstein-Barr Virus-Induced Lymphoproliferative Syndrome After Multivisceral Transplantation," <i>Clin. Invest. Med.</i> 17: 621-625 (1994).	
↓		LENNETTE, et al., "Antibodies to LMP2A/2B in EBV-carrying malignancies," <i>Eur. J. Cancer</i> 31(11): 1875-1878 (1995).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box →



PTO/SB08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Compleat If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divisional 109/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 9 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	Y <sup>2</sup>
AJ		LEVITSKAYA, "Inhibition of Antigen Processing by the Internal Repeat Region of the Epstein-Barr Virus Nuclear Antigen-1," <i>Nature</i> 375:685-688 (1995).	
		LONGNECKER & KIEFF, "A second Epstein-Barr virus membrane protein (LMP2) is expressed in latent infection and colocalizes with LMP1," <i>J. Virol.</i> 64: 2319-2326 (1990).	
		MASSEN, et al., <i>Eur. J. Biochem.</i> 134: 32 (1983).	
		MAHALINGAM, et al., "Expression of protein encoded by Varicella-Zoster virus open reading frame 63 in latently infected human ganglionic neurons," <i>Proc. Nat'l. Acad. Sci., USA</i> 93: 2122-2124 (1996).	
		MAITLAND, "Frequency of EBV-DNA Detection in Sjogren's Syndrome," <i>Am. J. Med.</i> 96:97 (1994).	
		MARIETTE, et al., "Detection of Epstein-Barr Virus DNA by <i>in Situ</i> Hybridization and Polymerase Chain Reaction in Patients with Sjogren's Syndrome," <i>Am. J. Med.</i> 90:286-294 (1991).	
		MARKMAN, <i>Semin. Oncol.</i> 18: 248-254 (1991).	
		MEANS, et al., <u>Chemical modifications of proteins</u> Holden-Day: San Francisco, pp. 105-110 (1971).	
		MEARES, et al., <i>Anal. Biochem.</i> 142: 68-78 (1984).	
		MEIGNER, et al., <i>J. Infect. Dis.</i> 162: 313-321 (1990).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →




PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Complete if Known  Application Number	
				Divisional 109/718,693	
				Filing Date	
				August 22, 2003	
				First Named Inventor	
				John B. Harley	
				Group Art Unit	
				Examiner Name	
Sheet 10 of 15				Attorney Docket Number	
				OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS		
Examiner's Initials*	Cite No.*	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published
AJ		MERRIFIELD, <i>J. Am. Chem. Soc.</i> 85: 2149 (1964).
		MIYASHITA, et al., "Identification of the site of Epstein-Barr virus persistence in vivo as a resting B cell," <i>J. Virol.</i> 71: 4882-4891 (1997).
		MOCARSKI, "Cytomegaloviruses and their replication" in <i>Fields Virology</i> , 3 <sup>rd</sup> ed. (Fields, et al. eds.) Lippincott-Raven pp. 2447-2480 (1996).
		MORGAN, "Epstein-Barr Virus Vaccines," <i>Vaccine</i> 10:563-571 (1992).
		MORGAN, et al., "Validation of a First-Generation Epstein-Barr Virus Vaccine Preparation Suitable for Human Use," <i>J. Med. Virol.</i> 29:74-78 (1989).
		MORSHED, et al., "Increased Expression of Epstein-Barr Virus in Primary Biliary Cirrhosis Patients," <i>Gastroenterol. Jpn.</i> 27(6):751-758 (1992).
		MUJOO, et al., <i>Oncogene</i> 12:1617-1623 (1996).
		MUSAINI, et al., <i>Ann. Rheum. Dis.</i> 46: 837-42 (1987).
		MYERS, et al., <i>J. Immunol. Meth.</i> 121(1): 129-142 (1989).
		NAKABAYASHI, et al., <i>Rheumatol. Int.</i> 5: 61-7 (1985).

Examiner's Signature		Date Considered	8/5/05
----------------------	---	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Complete If Known		
			Application Number	Divisional of 09/718,693	
			Filing Date	August 22, 2003	
			First Named Inventor	John B. Harley	
			Group Art Unit		
Examiner Name					
Sheet	11	of	15	Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
A		NEWKIRK, et al., "Detection of Cytomegalovirus, Epstein-Barr Virus and Herpes Virus-6 in Patients with Rheumatoid Arthritis With or Without Sjogren's Syndrome," <i>Br. J. Rheum.</i> 33:317-322 (1994).	
		NG, et al., <i>Lancet</i> 1(8166): 447-9 (1980).	
		Ol, et al., "Chimeric antibodies," <i>BioTechniques</i> 4(3): 214 (1986).	
		PALLESEN, et al., "Expression of Epstein-Barr Virus Latent Gene Products in Tumor Cells of Hodgkin's Disease," <i>Lancet</i> 337(8737): 320-322 (1991).	
		PFLUGFELDER, et al., "Amplification of Epstein-Barr Virus Genomic Sequences in Blood Cells, Lacrimal Glands, and Tears from Primary Sjogren's Syndrome Patients," <i>Ophthalmology</i> 97:976-984 (1990).	
		PFLUGFELDER, et al., "Epstein-Barr Virus and the Lacrimal Gland Pathology of Sjogren's Syndrome," <i>Am. J. Pathol.</i> 143:49-64 (1993).	
		PLOTKIN, et al., <i>J. Infect. Dis.</i> 159: 860-865 (1989).	
		PLOTKIN, et al., <i>Infect. Immun.</i> 12: 521-527 (1975).	
		PLOTKIN, et al., <i>Rev. Infect. Dis.</i> 12: 827-838 (1990).	
		QUADRI, et al., <i>Nucl. Med. Biol.</i> 20: 559-570 (1993).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Complete If Known	
		Application Number	Divisional 109/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 12 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
A		REUSSER, et al., <i>J. Infect. Dis.</i> 166: 473-479 (1992).	
		RICKINSON & KIEFF, "Epstein-Barr virus" in <i>Fields Virology</i> , Lippincott-Raven, pp. 2397-2446 (1996).	
		RODWELL, et al., "Site-specific covalent modification of monoclonal antibodies: <i>in vitro</i> and <i>in vivo</i> evaluations," <i>Proc. Natl. Acad. Sci.</i> 83: 2632-2636 (1986).	
		ROWE, et al., <i>J. Gen. Virol.</i> 69: 1217-1228 (1988).	
		ROWLINSON, et al., <i>Cancer Res.</i> 47: 6528-6531 (1987).	
		SABBATINI, et al., "Autoantibodies from Patients with Systemic Lupus Erythematosus Bind a Shared Sequence of AmD and Epstein-Barr Virus-Encoded Nuclear Antigen EBNA 1," <i>Eur. J. Immunol.</i> 23:1146-1152 (1993).	
		SADZOT-DELVAUX & BENTIER, 24 <sup>th</sup> International Herpesvirus Workshop July 17-23 (Mass. Inst. Tech.) Abst. 9.009 (1999).	
		SADZOT-DELVAUX, et al., <i>J. Immunol.</i> 159: 2802 (1997).	
		SALACINSKI, et al., <i>Anal. Biochem.</i> 117: 136-146 (1981).	
		SCHMIDT, et al., "Proc. Natl. Acad. Sci. USA 88(21): 9478-9482 (1991).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO		Compleat If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Divis nal 109/718,693
		Filing Date	August 22, 2003
		First Named Inventor	John B. Harley
		Group Art Unit	
		Examiner Name	
Sheet 13 of 15	Attorney Docket Number	OMRF 177 DIV	

OTHER ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
A7		SCOTET, et al., <i>J. Exp. Med.</i> 184: 1771-1780 (1996).	
		SCOTET, et al., "Frequent enrichment for CD8 T cells reactive against common herpes viruses in chronic inflammatory lesions: towards a reassessment of the physiopathological significance of T cell clonal expansions found in autoimmune inflammatory processes," <i>Eur J. Immunol.</i> 29: 973-985 (1999).	
		SCULLEY, et al., "Reactions of Sera from Patients with Rheumatoid Arthritis, Systemic Lupus Erythematosus and Infectious Mononucleosis to Epstein-Barr Virus-Induced Polypeptides," <i>J. Gen. Virol.</i> 67:2253-2258 (1986).	
		SINGH, et al., "Decreased Incidence of Viral Infections in Liver Transplant Recipients - Possible Effects of FK506?," <i>Digestive Dis. Sci.</i> 39:15-18 (1994).	
		SNOECK, et al., <u>Multidisciplinary approach to understanding cytomegalovirus disease</u> <i>Excerpta Medica: Amsterdam</i> , pp. 269-278 (1993).	
		SPAETE, <i>Transplant Proc.</i> 23: 90-96 (1991).	
		SPIRA, et al., <i>J. Immunol. Meth.</i> 74: 307 (1984).	
		STEWLEWSKI, et al., "Isolation and characterization of anti-monosialoganglioside monoclonal antibody 19-9 class-switch variants," <i>Proc. Natl. Acad. Sci., USA</i> 82: 8653-8657 (1985).	
		STRAUS, et al., <i>Ann. Int. Med.</i> 108: 221 (1988).	
		SUMAYA, et al., "Increased Prevalence and Titer of Epstein-Barr Virus Antibodies in Patients with Multiple Sclerosis," <i>Ann. Neurol.</i> 17:371-377 (1985).	

Examiner's Signature		Date Considered	8/5/05
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →



PTO/SB08A (10-95)  
Approved for use through 10/31/99. OMAB 0651-0001  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Compleat If Kn wn	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicati n Number	Divisi nal 109/718,693
				Filing Date	August 22, 2003
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	14	of	15	Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>4</sup>
A		SUN, et al., <i>Hybridoma</i> 5(Supp1): S17 (1986).	
		SUNDBERG, et al., <i>Nature</i> 250: 587-588 (1974).	
		TAKEI, et al., <i>Int. Immunol.</i> 9: 739-743 (1997).	
		TAN, <i>Rev. Inf. Dis.</i> 1: 997-1006 (1979).	
		TATEISHI, et al., "Spontaneous Production of Epstein-Barr Virus by B Lymphoblastoid Cell Lines Obtained from Patients with Sjogren's Syndrome," <i>Arthritis Rheum.</i> 36:827-835 (1993).	
		THORLEY-LAWSON, et al., "Epstein-Barr virus and the B cell: that's all it takes," <i>Trends in Microbiology</i> 4(5): 204-208 (1996).	
		TODA, et al., "Sjogren's syndrome (SS) and Epstein-Barr virus (EBV) reactivation," in <i>Lacrimal Gland, Tear Film, and Dry Eye Syndrome</i> , (D.A. Sullivan, ed.) pp. 647-650 (Plenum Press, New York 1994).	
		TSAI, et al., "Detection of Epstein-Barr Virus and Cytomegalovirus Genome in White Blood Cells from Patients with Juvenile Rheumatoid Arthritis and Childhood Systemic Lupus Erythematosus," <i>Int. Arch. Allergy Immunol.</i> 106:235-240 (1995).	
	VENABLES, et al., "Persistence of Epstein-Barr Virus in Salivary Gland Biopsies from Healthy Individuals and Patients with Sjogren's Syndrome," <i>Clin. Exp. Immunol.</i> , 75:359-364 (1989).		
	VENABLES, et al., "The Response to Epstein-Barr Virus Infection in Sjogren's Syndrome," <i>J. Autoimmunity</i> 2:439-448 (1989).		

Examiner's Signature		Date Considered	8/5/05
----------------------	--	-----------------	--------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO				Complete If Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				Applicant Number	Divisional 109/718,693
				Filing Date	August 22, 2003
				First Named Inventor	John B. Harley
				Group Art Unit	
				Examiner Name	
Sheet	15	of	15	Attorney Docket Number	OMRF 177 DIV

OTHER ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
AJ		VENABLES, et al., <i>Arthr. Rheum.</i> 24: 1459-1468 (1981).	
		VRISENDORP, et al., "Radioimmunoglobulin therapy" in <i>High Dose Cancer Therapy</i> (Armitage, et al. eds) Williams & Wilkins: Baltimore, pp. 84-123 (1992).	
		WAGSTAFF, et al., "Aciclovir - A Reappraisal of its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Efficacy," <i>Drugs</i> 47:153-205 (1994).	
		WANG, et al., <i>Radiat. Res.</i> 141: 292-302 (1995).	
		WARNER & CARP, "Multiple Sclerosis Etiology - an Epstein-Barr Virus Hypothesis," <i>Med. Hypotheses</i> 25:93-97 (1988).	
		WATSON, et al., "Certain Properties Make Substances Antigenic," in <i>Molecular Biology of the Gene</i> , Fourth Edition, page 836, paragraph 3, (The Benjamin/Cummings Publishing Company, Menlo Park, 1987).	
		WHITLEY, "Herpes Simplex viruses" in <i>Field's Virology</i> Lippincott-Raven, pp. 2297-2330 (1996).	

Examiner's Signature		Date Considered	8/15/05
----------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.